Impaired lipid metabolism in idiopathic pulmonary alveolar proteinosis

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Tian, Xinlun ^a   Luo, Jinmei ^a   Xu, Kai Feng ^a   Wang, Lan ^a   Zhou, Jiong ^a   Feng, Ruie ^a   Gui, Yaosong ^a   Wang, Juan ^a   Xu, Wenbing ^a   Xiao, Yi ^a   Zhu, Yuanjue ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

high density lipoprotein cholesterol; lipid; pulmonary alveolar proteinosis; triglyceride

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYGEN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LUNG ALVEOLUS PROTEINOSIS; MALE; METABOLIC DISORDER; OXYGEN TENSION; TRIACYLGLYCEROL BLOOD LEVEL; VOLUNTEER; BLOOD; LUNG; LUNG ALVEOLUS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PRESSURE; RETROSPECTIVE STUDY; VITAL CAPACITY;

ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LIPID METABOLISM; LIPIDS; LUNG; MALE; MIDDLE AGED; OXYGEN; PARTIAL PRESSURE; PULMONARY ALVEOLAR PROTEINOSIS; PULMONARY ALVEOLI; RETROSPECTIVE STUDIES; TRIGLYCERIDES; VITAL CAPACITY;

EID: 79953855918     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-54     Document Type: Article

References (31)

1. Pulmonary alveolar proteinosis progress in the first 44 years. JF Seymour JJ Presneill, Am J Respir Crit Care Med 2002 166 215 235 10.1164/rccm.2109105 12119235 (Pubitemid 34765459)
2. Pulmonary alveolar proteinosis. BC Trapnell JA Whitsett K Nakata, N Engl J Med 2003 349 2527 2539 10.1056/NEJMra023226 14695413 (Pubitemid 38010079)
3. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. I Huizar MS Kavuru, Curr Opin Pulm Med 2009 15 491 498 10.1097/MCP. 0b013e32832ea51c 19561506
4. Secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome. L Xie TM Zhao QY Wang LA Chen AM Li DT Wang F Qi YN Liu, Chin Med J 2007 120 1114 1116 17637233 (Pubitemid 47180890)
5. The lipids of pulmonary surfactant: dynamics and interactions with proteins. JJ Batenburg HP Haagsman, Prog Lipid Res 1998 37 235 276 10.1016/S0163-7827(98)00011-3 10193527 (Pubitemid 28421193)
6. Serum cholestenoic acid as a potential marker of pulmonary cholesterol homeostasis: increased levels in patients with pulmonary alveolar proteinosis. S Meaney TL Bonfield M Hansson A Babiker MS Kavuru MJ Thomassen, J Lipid Res 2004 45 2354 2360 10.1194/jlr.M400302-JLR200 15466366 (Pubitemid 39602983)
7. Guideline of prevention and treatment of adult dyslipidemia in China. Chinese committee of prevention and treatment of dyslipidemia in Chinese adults, Chin J Cardiovasc Dis 2007 35 390 419 (Chinese)
8. Standardisation of spirometry. MR Miller J Hankinson V Brusasco F Burgos R Casaburi A Coates R Crapo P Enright CP van der Grinten P Gustafsson R Jensen DC Johnson N MacIntyre R McKay D Navajas OF Pedersen R Pellegrino G Viegi J Wanger ATS/ERS Task Force, Eur Respir J 2005 26 319 338 10.1183/09031936.05. 00034805 16055882 (Pubitemid 41079078)
9. Standardisation of the measurement of lung volumes. J Wanger JL Clausen A Coates OF Pederson V Brusasco F Burgos R Casaburi R Crapo P Enright CP van der Grinten P Gustafsson J Hankinson R Jensen D Johnson N Macintyre R McKay MR Miller D Navajas R Pellegrino G Viegi, Eur Respir J 2005 26 511 522 10.1183/09031936.05.00035005 16135736 (Pubitemid 41264217)
10. Satndardisation of the single-breath determination of carbon monoxide uptake in the lung. N Macintyre RO Crapo G Viegi DC Johnson CP van der Grinten V Brusasco F Burgos R Casaburi A Coates P Enright P Gustafsson J Hankinson R Jensen R McKay MR Miller D Navajas OF Pedersen R Pellegrino J Wanger, Eur Respir J 2005 26 720 735 10.1183/09031936.05.00034905 16204605 (Pubitemid 41448672)
11. Insulin resistance in pulmonary arterial hypertension. RT Zamanian G Hansmann S Snook D Lilienfeld KM Rappaport GM Reaven M Rabinovitch RL Doyle, Eur Respir J 2009 33 318 324 10.1183/09031936.00000508 19047320
12. Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? SK Huang M Peters-Golden, Chest 2008 133 1442 1450 10.1378/chest.08-0306 18574287 (Pubitemid 351899641)
13. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. MS Kavuru EJ Sullivan R Piccin MJ Thomassen JK Stoller, Am J Respir Crit Care Med 2000 161 1143 1148 10764303 (Pubitemid 30243821)
14. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Y Inoue BC Trapnell R Tazawa T Arai T Takada N Hizawa Y Kasahara K Tatsumi M Hojo T Ichiwata N Tanaka E Yamaguchi R Eda K Oishi Y Tsuchihashi C Kaneko T Nukiwa M Sakatani JP Krischer K Nakata Japanese Center of the Rare Lung Diseases Consortium, Am J Respir Crit Care Med 2008 177 752 762 10.1164/rccm.200708-1271OC 18202348 (Pubitemid 351490562)
15. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. T Sakagami K Uchida T Suzuki BC Carey RE Wood SE Wert JA Whitsett BC Trapnell M Luisetti, N Engl J Med 2009 361 2679 2681 10.1056/NEJMc0904077 20042763
16. GM-CSF regulates protein and lipid catabolism by alveolar macrophages. M Yoshida M Ikegami JA Reed ZC Chroneos JA Whitsett, Am J Physiol Lung Cell Mol Physiol 2001 280 379 L386 11159019
17. Quantitative analysis of longitudinal response to aerosolized GM-CSF in two adolescents with autoimmune pulmonary alveolar proteinosis. TE Robinson BC Trapnell ML Goris LM Quittell DN Cornfield, Chest 2009 135 842 848 10.1378/chest.08-1317 19265094
18. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. MS Kavuru EJ Sullivan R Piccin MJ Thomassen JK Stoller, Am J Respir Crit Care Med 2000 161 1143 1148 10764303 (Pubitemid 30243821)
19. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. R Tazuwa BC Trapnell Y Inoue T Arai T Takada Y Nasuhara N Hizawa Y Kasahara K Tatsumi M Hojo H Ishii M Yokoba N Tanaka E Yamaguchi R Eda Y Tsuchihashi K Morimoto M Akira M Terada J Otsuka M Ebina C Kaneko T Nukiwa JP Krischer K Akazawa K Nakata, Am J Respir Crit Care Med 2010 181 1345 1354 10.1164/rccm.200906-0978OC 20167854
20. Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor. T Ishibashi K Yokoyama J Shindo, Arterioscler Thromb 1994 14 1534 1541 7918302
21. GM-CSF in inflammation and autoimmunity. JA Hamilton, Trends Immunol 2002 23 403 408 10.1016/S1471-4906(02)02260-3 12133803 (Pubitemid 34804636)
22. Inflammation and metabolic disorders. GS Hotamisligil, Nature 2006 444 860 867 10.1038/nature05485 17167474 (Pubitemid 46024993)
23. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. C Popa MG Netea PL van Riel JW van der Meer AF Stalenhoef, J Lipid Res 2007 48 751 762 10.1194/jlr.R600021-JLR200 17202130
24. Continuous infusion of interleukin-1 beta in rats induces a profound fall in plasma levels of cholesterol and triglycerides. AR Hermus CG Sweep PN Demacker MJ van der Meer PW Kloppenborg JW van der Meer, Arterioscler Thromb 1992 12 1036 1043 1525118
25. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. TL Bonfield CF Farver BP Barna A Malur S Abraham B Raychaudhuri MS Kavuru MJ Thomassen, Am J Respir Cell Mol Biol 2003 29 677 682 10.1165/rcmb.2003-0148OC 12805087 (Pubitemid 38045936)
26. Restoration of PPAR- reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. A Malur AD Baker AJ McCoy G Wells BP Barna MS Kavuru AG Malur MJ Thomassen, Am J Physiol Lung Cell Mol Physiol 2011 300 73 L80 10.1152/ajplung.00128.2010 21036914
27. ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. MJ Thomassen BP Barna AG Malur TL Bonfield CF Farver A Malur H Dalrymple MS Kavuru M Febbraio, J Lipid Res 2007 48 2762 2768 10.1194/jlr.P700022-JLR200 17848583 (Pubitemid 350272860)
28. Prostaglandin and PPAR control of immune cell function. D Rotondo J Davidson, Immunology 2002 105 20 22 10.1046/j.0019-2805.2001.01361.x 11849311 (Pubitemid 34128036)
29. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. RM Touyz EL Schiffrin, Vascul Pharmacol 2006 45 19 28 10.1016/j.vph.2005.11.014 16782410 (Pubitemid 43963482)
30. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. RR Henry AM Lincoff S Mudaliar, Lancet 2009 374 126 135 10.1016/S0140-6736(09)60870-9 19515415
31. Autoantibody against granulocyte macrophage colony- stimulating factor and other serum markers in pulmonary alveolar proteinosis. KF Xu Y Chen ZJ Guo YJ Zhu, Zhonghua Jie He He Hu Xi Za Zhi 2004 27 824 8 (Chinese) 15730782